XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Income Statement [Abstract]        
Revenues $ 27,872,000 $ 21,553,000 $ 54,152,000 $ 34,629,000
Operating expenses:        
Research and development 60,086,000 41,523,000 116,520,000 83,002,000
General and administrative 16,486,000 17,927,000 32,634,000 34,046,000
Total operating expenses 76,572,000 59,450,000 149,154,000 117,048,000
Loss from operations (48,700,000) (37,897,000) (95,002,000) (82,419,000)
Interest and other income, net 1,550,000 1,932,000 2,176,000 3,480,000
Loss before taxes (47,150,000) (35,965,000) (92,826,000) (78,939,000)
Income tax expense 24,000 0 287,000 0
Net loss (47,174,000) (35,965,000) (93,113,000) (78,939,000)
Net loss attributable to non-controlling interest (5,000) (36,000) (11,000) (97,000)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders $ (47,169,000) $ (35,929,000) $ (93,102,000) $ (78,842,000)
Earnings per share, basic (in dollars per share) $ (0.33) $ (0.26) $ (0.65) $ (0.62)
Earnings per share, diluted (in dollars per share) $ (0.33) $ (0.26) $ (0.65) $ (0.62)
Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) 143,984 138,977 143,550 127,519
Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) 143,984 138,977 143,550 127,519